Czernin Johannes, Benz Matthias R, Allen-Auerbach Martin S
Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
Methods Mol Biol. 2011;727:141-70. doi: 10.1007/978-1-61779-062-1_9.
Diagnostic imaging modalities utilized in the care of cancer patients must fulfill several requirements: they must diagnose and characterize tumors with high accuracy, must reliably stage and restage the disease, and should allow for monitoring the effects of therapeutic interventions on the course of the disease. They should impact management by guiding treating physicians to appropriate individualized treatment strategies. There is ample evidence that positron emission tomography (PET) and PET-computed tomography (CT) imaging can meet these requirements. This chapter discusses the role and contributions of PET and PET-CT imaging using (18)F-fluorodeoxyglucose in diagnosing, staging, restaging, and treatment monitoring of breast cancer. Novel molecular imaging probes and devices that have been developed and translated into early clinical research protocols are also introduced.
它们必须以高准确性诊断和表征肿瘤，必须可靠地对疾病进行分期和重新分期，并且应该能够监测治疗干预对疾病进程的影响。它们应该通过指导治疗医生采用适当的个体化治疗策略来影响治疗管理。有充分证据表明，正电子发射断层扫描（PET）和PET计算机断层扫描（CT）成像能够满足这些要求。本章讨论了使用（18）F-氟脱氧葡萄糖的PET和PET-CT成像在乳腺癌诊断、分期、重新分期和治疗监测中的作用与贡献。还介绍了已开发并转化为早期临床研究方案的新型分子成像探针和设备。
